התמחויות

Schering-Plough Announces European Union Broadens Desloratadine Indications to Indoor and Outdoor Allergies


KENILWORTH, NJ — June 4, 2002 —

Schering-Plough Corporation today announced that the European Commission of the European Union (EU) has granted a marketing authorization for desloratadine (marketed as Clarinex® in the United States) that broadens the indications for the once-daily nonsedating antihistamine to include the treatment of allergic rhinitis (AR) caused by perennial indoor and seasonal outdoor allergens.

This new indication encompasses the previously approved indication of seasonal allergic rhinitis (SAR) caused by outdoor allergens. Marketed in the EU under the brand names Aerius, Neoclarityn and Azomyr, desloratadine is also approved in the EU for the treatment of the symptoms of chronic idiopathic urticaria (CIU), such as itching or hives. Allergic rhinitis, which is considered to encompass both the symptoms of outdoor seasonal allergies and the symptoms of indoor perennial allergies, affects approximately 60 million people in Europe.

 An estimated 40 to 50 percent of people with allergies are believed to suffer from both seasonal and perennial allergies, 20 to 30 percent from seasonal allergies alone, and 15 to 30

percent from perennial allergies alone, according to Decision Resources, Inc.

תגובות רוצה להצטרף לדיון?

אין תגובות עדיין. היה הראשון להגיב!

מאמרים

לכל המאמרים

כניסת צוות רפואי

הכניסה לאתר מותרת אך ורק לצוות הרפואי

לקבלת קוד אימות לנייד ולמייל, יש למלא את כתובת המייל ואת מספר הטלפון שלך

עדיין לא נרשמת? באפשרותך לבצע רישום כאן